Challenges and pitfalls in the management of endocrine toxicities from immune checkpoint inhibitors: a case presentation of synchronous thyrotoxicosis and primary adrenal insufficiency in a melanoma patient-Reference-Cited by-同舟云学术

Challenges and pitfalls in the management of endocrine toxicities from immune checkpoint inhibitors: a case presentation of synchronous thyrotoxicosis and primary adrenal insufficiency in a melanoma patient

Published:2024-02-29 Issue: Volume: Page:
ISSN:1109-3099
Container-title:Hormones
language:en
Short-container-title:Hormones

Author:

Spagnolo Calogera Claudia,Campo Irene,Campennì Alfredo,Cardile Davide,Cannavò Salvatore,Silvestris Nicola,Santarpia Mariacarmela,Ruggeri Rosaria Maddalena

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s42000-024-00535-0.pdf

Reference38 articles.

1. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264. https://doi.org/10.1038/nrc3239

2. Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N et al (2022) Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol 23:781–792. https://doi.org/10.1016/S1470-2045(22)00226-1

3. Niu J, Maurice-Dror C, Lee DH, Kim DW, Nagrial A, Voskoboynik M et al (2022) First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer. Ann Oncol 33:169–180. https://doi.org/10.1016/j.annonc.2021.11.002

4. Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I et al (2022) COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non-small-cell lung cancer. J Clin Oncol 40:3383–3393. https://doi.org/10.1200/JCO.22.00227

5. Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI (2022) Immunotherapy in lung cancer: current landscape and future directions. Front Immunol 13:823618. https://doi.org/10.3389/fimmu.2022.823618